The study compared the levels of MMP-2,7,8,9, and TIMP-1 in blood serum of healthy people ( N =97) and patients with primary renal cell carcinoma ( N =93) to assess relevance of these markers to prognosis of overall survival of these patients, which were followed-up over 1 to 45 months (median 26 months). To evaluate the survival with the Kaplan—Meier estimator, the median values of examined markers in the total group of patients were taken as the threshold levels. This estimator showed that the high levels of serum MMP-7 and MMP-8 were indicative for unfavorable prognosis in the total group of patients with r enal cell cancer. Of them, the most significant marker was the level of MMP-7: at its low level (<6.3 ng/ml), a 3-year survival was 93%, whereas survival dropped down to 51% at a higher value of this marker ( p <0.001). For MMP-8, the threshold level was 51 ng/ml, and the corresponding survivals were 78 and 58% ( p <0.01). The level of MMP-7 was also prognostically significant for the patients with stage I kidney cancer: during a 3-year follow-up, all the patients with low MMP-7 were alive, while the 3-year survival of the patients with a high level of MMP-7 was only 72% ( p =0.02). There were the declining trends for survival at high TIMP-1 and low MMP-2. In contrast, the level of MMP-9 virtually did not correlate with survival of the patients with renal cell cancer.

中文翻译：

---

基质金属蛋白酶 2、7、8、9 及其 1 型组织抑制剂在肾癌患者血清中的预后作用

该研究比较了健康人（N=97）和原发性肾细胞癌患者（N=93）血清中 MMP-2、7、8、9 和 TIMP-1 的水平，以评估这些标志物与这些患者的总生存期预后，随访时间超过 1 至 45 个月（中位数 26 个月）。为了使用 Kaplan-Meier 估计器评估生存率，将整个患者组中检查标志物的中值作为阈值水平。该估计值表明，血清 MMP-7 和 MMP-8 的高水平表明肾细胞癌总患者的预后不良。其中，最显着的标志物是 MMP-7 的水平：在其低水平 (<6.3 ng/ml) 时，3 年生存率为 93%，而在该标志物的较高值下，生存率下降至 51% ( p <0.001)。对于 MMP-8，阈值为 51 ng/ml，相应的存活率分别为 78% 和 58% (p <0.01)。MMP-7 水平对 I 期肾癌患者也具有预后意义：在 3 年的随访期间，所有 MMP-7 低的患者都存活，而 MMP-7 低的患者的 3 年生存率MMP-7 的高水平仅为 72% (p = 0.02)。高 TIMP-1 和低 MMP-2 的存活率有下降的趋势。相比之下，MMP-9 的水平实际上与肾细胞癌患者的存活率无关。而MMP-7高水平患者的3年生存率仅为72%（p=0.02）。高 TIMP-1 和低 MMP-2 的存活率有下降的趋势。相比之下，MMP-9 的水平实际上与肾细胞癌患者的存活率无关。而MMP-7高水平患者的3年生存率仅为72%（p=0.02）。高 TIMP-1 和低 MMP-2 的存活率有下降的趋势。相比之下，MMP-9 的水平实际上与肾细胞癌患者的存活率无关。